BCT BriaCell Therapeutics Corp

Note from BriaCell Management – October is Breast Cancer Awareness Month

Note from BriaCell Management – October is Breast Cancer Awareness Month
EN
01/10/2020

Underlying

BCTBriaCell Therapeutics Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BriaCell Therapeutics Corp

 PRESS RELEASE
Free
BCT BriaCell Therap...

“Eleven clinical trials that will shape medicine in 2026” – BriaCell P...

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVIDBriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026”BriaCell anticipates reporting top line data as early as H1-2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX,...

December 18, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Cli...

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaCell’s regimenMaturing Phase 2 study data continues to support meaningful clinical benefit of the Bria-IMT regimen with outstanding long-term survival No toxicity related discontinuations in Phase 3 PHILADELPHIA and VANCOUVER, British...

December 10, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data...

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient interestTopline interim data readout expected in 1H2026 Phase 3 combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

December 9, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS®...

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025 Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from the pivotal Phase 3 The pivotal Phase 3 study of Bria-IMT+CPI in advanced metastatic breast cancer is ongoing with an interim analysis expected in 1H2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTX...

December 2, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABC...

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025 Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal Phase 3 studies The pivotal Phase 3 study of Bria-IMT+CPI is ongoing with an interim analysis expected in H1-2026The Bria-IMT regimen has received Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq:...

November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch